Title:
ANTI-CLDN18.2 ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/232080
Kind Code:
A1
Abstract:
The present invention belongs to the field of biomedicine. Disclosed in the present invention are an anti-CLDN18.2 antibody, and an antibody-drug conjugate and use thereof. In some embodiments, the antibody-drug conjugate is a compound represented by formula I or a stereoisomer or a pharmaceutically acceptable salt or solvate thereof. The anti-CLDN18.2 antibody and the antibody-drug conjugate can be used for treating diseases associated with CLDN18.2 expression.
More Like This:
| WO/2023/121370 | LIVER-TARGETED SUBSTANCE AND USE THEREOF |
| JP2020508331 | Stabilized antibody solution |
| WO/2023/218378 | COMBINATION OF AN ANTIBODY SPECIFIC FOR A TUMOR ANTIGEN AND A CD47 INHIBITOR |
Inventors:
XIAO CUIZHEN (CN)
QIN CHAO (CN)
MAI SIQI (CN)
YU JIN-CHEN (CN)
LI SHENGFENG (CN)
QIN CHAO (CN)
MAI SIQI (CN)
YU JIN-CHEN (CN)
LI SHENGFENG (CN)
Application Number:
PCT/CN2023/097470
Publication Date:
December 07, 2023
Filing Date:
May 31, 2023
Export Citation:
Assignee:
BIO THERA SOLUTIONS LTD (CN)
International Classes:
A61K47/68; A61K31/4745; A61K45/06; A61P35/00; C07K5/117
Foreign References:
| CN115429893A | 2022-12-06 | |||
| CN111110862A | 2020-05-08 | |||
| CN107667118A | 2018-02-06 | |||
| CN114269389A | 2022-04-01 |
Download PDF: